Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N. Thatcher, Alex Y. Chang, Purvish Mahendra Parikh et al. · The Lancet · 2005
Cited by 2,081 works. doi:10.1016/s0140-6736(05)67625-8
Authors
- N. Thatcher
- Alex Y. Chang
- Purvish Mahendra Parikh
- José Rodrigues Pereira
- Tudor–Eliade Ciuleanu
- Joachim von Pawel
- Sumitra Thongprasert
- E.H. Tan
- Kristine Pemberton
- Venice Rosalie Archer
- Kevin Carroll
References
- Global cancer statistics
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- Global Cancer Statistics, 2002
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer